Gary Schwartz, MD
The recent FDA approval of durvalumab (Imfinzi) in locally advanced unresectable stage III non–small cell lung cancer (NSCLC) marks a new era in the landscape, as the agent showed a significant improvement in progression-free survival (PFS) in a phase III trial.
The approval was based on the results of the PACIFIC trial that examined the PD-L1 inhibitor versus placebo. Results showed an improved median PFS of 11.2 months compared with placebo (16.8 vs 5.6 months; HR, 0.52; 95% CI, 0.42-0.65; P
<.0001). The 12-month PFS rates were 55.9% versus 35.3%, and the 18-month PFS rate was 44.2% versus 27.0% for durvalumab and placebo, respectively.
... to read the full story